[go: up one dir, main page]

SI2301544T1 - Derivati kinolina kot vmesne spojine za mikobakterijske inhibitorje - Google Patents

Derivati kinolina kot vmesne spojine za mikobakterijske inhibitorje

Info

Publication number
SI2301544T1
SI2301544T1 SI200332211T SI200332211T SI2301544T1 SI 2301544 T1 SI2301544 T1 SI 2301544T1 SI 200332211 T SI200332211 T SI 200332211T SI 200332211 T SI200332211 T SI 200332211T SI 2301544 T1 SI2301544 T1 SI 2301544T1
Authority
SI
Slovenia
Prior art keywords
intermediates
quinoline derivatives
mycobacterial inhibitors
mycobacterial
inhibitors
Prior art date
Application number
SI200332211T
Other languages
English (en)
Inventor
Jerome Emile Georges Guillemont
Marc Gaston Venet
Laurence Francoise Bernadette Decrane
Daniel Frank Jean Vernier
Imre Christian Francis Csoka
Original Assignee
Janssen Pharmaceutica, N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2301544(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica, N.V. filed Critical Janssen Pharmaceutica, N.V.
Publication of SI2301544T1 publication Critical patent/SI2301544T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200332211T 2002-07-25 2003-07-18 Derivati kinolina kot vmesne spojine za mikobakterijske inhibitorje SI2301544T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39871102P 2002-07-25 2002-07-25
EP10154018A EP2301544B1 (en) 2002-07-25 2003-07-18 Quinoline derivatives as intermediates to mycobacterial inhibitors

Publications (1)

Publication Number Publication Date
SI2301544T1 true SI2301544T1 (sl) 2013-01-31

Family

ID=31188461

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200332211T SI2301544T1 (sl) 2002-07-25 2003-07-18 Derivati kinolina kot vmesne spojine za mikobakterijske inhibitorje
SI200331819T SI1527050T1 (sl) 2002-07-25 2003-07-18 Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200331819T SI1527050T1 (sl) 2002-07-25 2003-07-18 Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji

Country Status (37)

Country Link
US (1) US7498343B2 (sl)
EP (2) EP1527050B1 (sl)
JP (1) JP4484703B2 (sl)
KR (1) KR100733577B1 (sl)
CN (2) CN101070304B (sl)
AP (1) AP2421A (sl)
AR (1) AR040673A1 (sl)
AT (1) ATE463482T1 (sl)
AU (1) AU2003262529B2 (sl)
BE (1) BE2014C051I2 (sl)
BR (1) BRPI0312927B8 (sl)
CA (1) CA2493225C (sl)
CY (3) CY1111882T1 (sl)
DE (1) DE60332023D1 (sl)
DK (2) DK2301544T3 (sl)
EA (1) EA008937B1 (sl)
ES (2) ES2395237T3 (sl)
FR (1) FR14C0060I2 (sl)
HR (2) HRP20120190B1 (sl)
HU (1) HUS1400047I1 (sl)
IL (2) IL166457A (sl)
IS (1) IS2914B (sl)
LU (1) LU92520I2 (sl)
ME (1) ME00131B (sl)
MX (1) MXPA05001052A (sl)
MY (1) MY143564A (sl)
NL (1) NL300684I2 (sl)
NO (2) NO329935B1 (sl)
NZ (1) NZ538391A (sl)
PL (1) PL222801B1 (sl)
PT (2) PT1527050E (sl)
RS (1) RS52431B (sl)
SI (2) SI2301544T1 (sl)
TW (1) TWI323730B (sl)
UA (1) UA82198C2 (sl)
WO (1) WO2004011436A1 (sl)
ZA (1) ZA200500680B (sl)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE444068T1 (de) * 2004-01-23 2009-10-15 Janssen Pharmaceutica Nv Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
NZ547277A (en) 2004-01-23 2009-08-28 Janssen Pharmaceutica Nv Substituted quinolines and their use as mycobacterial inhibitors
EA011572B9 (ru) * 2004-01-29 2018-01-31 Янссен Фармацевтика Н.В. Производные хинолина для применения в качестве микобактериальных ингибиторов
ATE390925T1 (de) * 2004-05-28 2008-04-15 Janssen Pharmaceutica Nv Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ME02935B (me) * 2004-09-28 2018-04-20 Janssen Pharmaceutica Nv Vezujući domen bakterijske atp sintaze
JP2006182755A (ja) * 2004-12-24 2006-07-13 Janssen Pharmaceut Nv 潜伏性結核の処置
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
BRPI0611166B1 (pt) * 2005-05-25 2022-01-25 Janssen Pharmaceutica N.V. Processo para isolar (as,ssr)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil- betafenil-3-quinolinaetanol
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained
TWI380819B (zh) * 2005-06-08 2013-01-01 Janssen Pharmaceutica Nv 用作抗細菌劑之喹啉衍生物
EA010601B1 (ru) * 2005-06-09 2008-10-30 Янссен Фармацевтика Н.В. Производные хинолина в качестве антибактериальных агентов
KR101318181B1 (ko) * 2005-06-09 2013-10-16 얀센 파마슈티카 엔.브이. 항균제로서의 퀴놀린 유도체
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
DK1898909T3 (en) * 2005-06-28 2017-02-06 Janssen Pharmaceutica Nv QUINOLIN DERIVATIVES AS ANTIBACTERIAL AGENTS
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO3077B1 (ar) * 2005-07-28 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينولين مضادة للبكتيريا
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
WO2007022946A1 (de) * 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2970B1 (en) 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2685B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
CN102249935B (zh) * 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
PL2841425T3 (pl) 2012-04-27 2016-10-31 Antybakteryjne pochodne chinoliny
US9617244B2 (en) 2012-04-27 2017-04-11 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
US9428474B2 (en) 2012-12-21 2016-08-30 Janssen Sciences Ireland Uc Antibacterial compounds
RU2530493C1 (ru) * 2013-04-22 2014-10-10 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ их получения и применение соединений для лечения инфекционных заболеваний микобактериальной природы, в частности туберкулеза
CN105017147B (zh) * 2014-04-30 2019-02-01 中国医学科学院药物研究所 一种回收和利用Bedaquiline立体化学异构体的方法
CN105085396B (zh) * 2014-05-07 2017-08-08 国药集团国瑞药业有限公司 用于制备贝达喹啉的中间体及其制备方法和应用
CN105085395B (zh) * 2014-05-07 2017-09-26 国药集团国瑞药业有限公司 贝达喹啉的制备方法
CN105198808B (zh) * 2014-05-27 2017-08-25 北京万生药业有限责任公司 一种高效生产贝达喹啉的方法
CN105175329B (zh) * 2014-06-10 2017-09-19 重庆圣华曦药业股份有限公司 一种贝达喹啉消旋体的合成路线及方法
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
BR112017000764B1 (pt) * 2014-07-14 2022-07-12 Shanghai Jia Tan Pharmatech Co. Ltd. Composto, método para preparar o composto e uso do composto
CN105440051B (zh) * 2014-09-19 2019-07-05 重庆医药工业研究院有限责任公司 一种抗结核的噻吩吡啶衍生物
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
CZ201534A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
CZ201533A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Způsob izolace směsi enantiomerů
CZ201535A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
HRP20230616T1 (hr) 2015-01-27 2023-09-29 Janssen Pharmaceutica Nv Disperzivni pripravci
WO2016174673A1 (en) * 2015-04-29 2016-11-03 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Anti-phytopathogenic compositions
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
AU2016287478B2 (en) 2015-07-02 2021-10-21 Janssen Sciences Ireland Uc Antibacterial compounds
CN105061387A (zh) * 2015-07-17 2015-11-18 苏州大学 二芳基醚类稠环类化合物、制备方法和用途
WO2017015793A1 (zh) * 2015-07-24 2017-02-02 浙江海正药业股份有限公司 一种分离贝达喹啉非对映异构体a的方法
US10196360B2 (en) 2015-10-20 2019-02-05 Zhejiang Hisun Pharmaceutical Co., Ltd. Crystal forms of bedaquiline fumarate and preparation methods therefor
WO2017121323A1 (zh) * 2016-01-13 2017-07-20 辰欣药业股份有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
EP3423449B1 (en) * 2016-03-03 2021-04-07 Council of Scientific and Industrial Research Substituted aurone alkaloids as anti-mycobacterial agents
US10508097B2 (en) * 2016-03-07 2019-12-17 The Global Alliance For Tb Drug Development, Inc. Antibacterial compounds and uses thereof
JP2019518046A (ja) 2016-06-16 2019-06-27 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌薬としての複素環式化合物
EA201990044A1 (ru) 2016-06-16 2019-05-31 Янссен Сайенсиз Айрлэнд Анлимитед Компани Гетероциклические соединения в качестве антибактериальных средств
US11224596B2 (en) 2017-03-01 2022-01-18 Janssen Sciences Ireland Unlimited Company PZA and cytochrome bc1 inhibitor combination treatment
RS65207B1 (sr) 2017-07-14 2024-03-29 Janssen Pharmaceutica Nv Formulacije bedakvilina sa dugim delovanjem
CN109384716B (zh) * 2017-08-11 2021-06-29 海创药业股份有限公司 一种氘代喹啉化合物及其制备和用途
JP2022516671A (ja) 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性抗酸菌症の処置における組合せ
WO2020161743A1 (en) 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
US20220340564A1 (en) 2019-09-13 2022-10-27 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2021057190A1 (zh) * 2019-09-29 2021-04-01 上海阳帆医药科技有限公司 喹啉类化合物、其制备方法和用途
US20220389008A1 (en) 2019-09-30 2022-12-08 Janssen Sciences Ireland Unlimited Company 4-quinolinone antibacterial compounds
US20220372033A1 (en) 2019-09-30 2022-11-24 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
PE20221725A1 (es) 2019-12-27 2022-11-04 Tecnimede Sociedade Tecnico Medicinal Sa Nuevos compuestos farmaceuticos
KR102303635B1 (ko) 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
JP2023532981A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
WO2022008643A1 (en) 2020-07-09 2022-01-13 Janssen Pharmaceutica Nv Long-acting formulations
WO2022008645A1 (en) 2020-07-09 2022-01-13 Janssen Pharmaceutica Nv Long-acting formulations
EP4243800A1 (en) 2020-11-12 2023-09-20 JANSSEN Pharmaceutica NV Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
KR20230157400A (ko) 2021-03-16 2023-11-16 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항박테리아성 화합물
KR20230157445A (ko) 2021-03-17 2023-11-16 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항박테리아성 화합물
AU2022240967A1 (en) 2021-03-17 2023-11-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
MX2024000111A (es) 2021-06-29 2024-01-19 Tecnimede Sociedade Tecnico Medicinal Sa Compuestos heterociclicos para el tratamiento de tuberculosis.
US20250034171A1 (en) 2021-10-28 2025-01-30 Janssen Sciences Ireland Unlimited Company Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
CN114835641B (zh) * 2022-05-07 2024-03-15 南京杰运医药科技有限公司 一种3-苄基-6-溴-2-甲氧基喹啉的合成方法
CN117050006A (zh) * 2022-05-13 2023-11-14 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用
EP4593834A1 (en) 2022-09-28 2025-08-06 JANSSEN Pharmaceutica NV Long-acting formulations
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
US20240199608A1 (en) * 2022-11-15 2024-06-20 Eli Lilly And Company Ahr agonists
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025068448A1 (en) 2023-09-28 2025-04-03 Janssen Pharmaceutica Nv Atp synthase inhibitors for use in the treatment of non-tuberculosis mycobacteria
WO2025181475A1 (en) 2024-02-27 2025-09-04 The University Of Liverpool Novel tuberculosis sterilization formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018326A1 (en) * 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
EP0991623A2 (en) * 1997-06-19 2000-04-12 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
WO1999037365A1 (en) * 1998-01-23 1999-07-29 Fire Armour Pte Ltd. Nozzle with axially and perpendicularly directed apertures
ES2201674T3 (es) * 1998-01-26 2004-03-16 Smithkline Beecham Plc Derivados de quinolina con propiedades antibacterianas.
US6819431B2 (en) * 2001-07-06 2004-11-16 Zygo Corporation Polymer retarder
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained

Also Published As

Publication number Publication date
DK2301544T3 (da) 2013-01-02
AU2003262529A1 (en) 2004-02-16
BR0312927A (pt) 2005-07-12
ME00131B (me) 2010-10-10
BE2014C051I2 (sl) 2022-08-09
ZA200500680B (en) 2006-08-30
UA82198C2 (uk) 2008-03-25
CY2014033I2 (el) 2016-04-13
EP1527050A1 (en) 2005-05-04
EP1527050B1 (en) 2010-04-07
BRPI0312927B1 (pt) 2018-07-10
LU92520I2 (fr) 2015-11-02
TWI323730B (en) 2010-04-21
US7498343B2 (en) 2009-03-03
HRP20120190A2 (hr) 2012-05-31
JP4484703B2 (ja) 2010-06-16
HRP20120190A8 (hr) 2012-07-31
RS52431B (sr) 2013-02-28
ES2395237T3 (es) 2013-02-11
NO2014021I1 (no) 2014-08-20
AP2421A (en) 2012-06-08
PL375523A1 (en) 2005-11-28
CA2493225C (en) 2012-03-20
CN101070304A (zh) 2007-11-14
IL166457A (en) 2011-10-31
DE60332023D1 (de) 2010-05-20
HRP20050045A2 (en) 2006-06-30
ES2343458T3 (es) 2010-08-02
IL166457A0 (en) 2006-01-15
EP2301544B1 (en) 2012-09-19
WO2004011436A1 (en) 2004-02-05
IS7620A (is) 2004-12-29
NO329935B1 (no) 2011-01-24
KR100733577B1 (ko) 2007-06-29
AU2003262529B2 (en) 2009-11-19
DK1527050T3 (da) 2010-07-19
MY143564A (en) 2011-05-31
CA2493225A1 (en) 2004-02-05
AR040673A1 (es) 2005-04-13
CY2014033I1 (el) 2016-04-13
JP2006504658A (ja) 2006-02-09
SI1527050T1 (sl) 2010-08-31
NL300684I2 (sl) 2016-10-11
EP2301544A1 (en) 2011-03-30
HK1113795A1 (en) 2008-10-17
HRP20050045B1 (hr) 2013-09-30
PL222801B1 (pl) 2016-09-30
MXPA05001052A (es) 2005-04-08
CN1325475C (zh) 2007-07-11
US20050148581A1 (en) 2005-07-07
NO2014021I2 (sl) 2014-08-20
PT2301544E (pt) 2012-12-10
EA008937B1 (ru) 2007-10-26
RS20050058A (sr) 2007-06-04
HRP20120190B1 (hr) 2017-06-02
NO20050476L (no) 2005-01-27
CY1111882T1 (el) 2015-11-04
CN101070304B (zh) 2011-10-26
KR20050033607A (ko) 2005-04-12
TW200410939A (en) 2004-07-01
HUS1400047I1 (hu) 2016-09-28
MEP9208A (en) 2010-06-10
FR14C0060I1 (sl) 2014-10-10
BRPI0312927B8 (pt) 2021-05-25
ATE463482T1 (de) 2010-04-15
IL202655A (en) 2012-04-30
FR14C0060I2 (fr) 2015-11-20
PT1527050E (pt) 2010-06-22
CN1671667A (zh) 2005-09-21
IS2914B (is) 2014-12-15
EA200500257A1 (ru) 2005-06-30
HK1083496A1 (en) 2006-07-07
CY1113497T1 (el) 2016-06-22
NZ538391A (en) 2005-10-28
AP2005003210A0 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
SI2301544T1 (sl) Derivati kinolina kot vmesne spojine za mikobakterijske inhibitorje
ZA200509319B (en) Quinoline derivatives as phosphodiesterase inhibitors
AU2003278088A1 (en) Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
EP1848430A4 (en) NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS
AU2003260345A1 (en) 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
IL177012A0 (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
AP2006003705A0 (en) Quinoline derivatives for use as mycobacterial inhibitors
ZA200603657B (en) Novel quinoline derivatives
PL372756A1 (en) Nicotinamide derivatives useful as pde4 inhibitors
PL376129A1 (en) Pyridazinone derivatives as gsk-3beta inhibitors
IL169691A0 (en) Malonamide derivatives as gamma-secretase inhibitors
IL165887A0 (en) Novel tetrahydropyridine derivatives as renin inhibitors
SG131944A1 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
GB0203193D0 (en) Nicotinamide derivatives useful as pde4 inhibitors
GB0317516D0 (en) Nicotinamide derivatives useful as PDE4 inhibitors
IL172793A0 (en) Nicotinamide derivatives useful as pde4 inhibitors
GB0317484D0 (en) Nicotinamide derivatives useful as pde4 inhibitors
GB0317509D0 (en) Nicotinamide derivatives useful as PDE4 inhibitors
GB0317472D0 (en) Nicotinamide derivatives useful as PDE4 inhibitors
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
PL376540A1 (pl) Pochodne diazepanów stosowane jako inhibitory LFA
GB0305916D0 (en) New N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors
AU2003207639A1 (en) Pyrimidine derivatives as rho-kinase inhibitors
GB0227139D0 (en) Nicotinamide derivatives useful as pde4 inhibitors
GB0224453D0 (en) Nicotinamide derivatives useful as PDE4 inhibitors